Transient Foxp3 + regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells

Immunology and Cell Biology

Volumn 91, Issue 1, 2013, Pages 105-114

  Mattarollo, Stephen R ^a,b   Steegh, Kim ^a   Li, Ming ^a   Duret, Helene ^a   Foong Ngiow, Shin ^a,c   Smyth, Mark J ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

alpha galactosylceramide; Foxp3 Treg; IFN g; immunotherapy; NKT cells; vaccine

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ANTINEOPLASTIC AGENT; CD44V ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17; L SELECTIN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; EFFECTOR CELL; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; LYMPHOCYTIC INFILTRATION; MELANOMA; MEMORY CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FORKHEAD TRANSCRIPTION FACTORS; GALACTOSYLCERAMIDES; INTERFERON-GAMMA; INTERLEUKIN-17; LYMPHOCYTE DEPLETION; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; NATURAL KILLER T-CELLS; T-LYMPHOCYTES, REGULATORY; VACCINATION;

MUS;

EID: 84872130879     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2012.58     Document Type: Article

References (52)

1. Smyth MJ, Thia KYT, Street SEA, Cretney E, Trapani JA, Taniguchi M et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000; 191: 661-668.
2. Mattarollo SR, Yong M, Tan L, Frazer IH, Leggatt GR. Secretion of IFN-{gamma} but not IL-17 by CD1d-restricted NKT cells enhances rejection of skin grafts expressing epithelial cell-derived antigen. J Immunol 2010.
3. Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, Hayakawa Y. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med 2005; 201: 1973-1985. (Pubitemid 41002933)
4. Crowe NY, Coquet JM, Berzins SP, Kyparissoudis K, Keating R, Pellicci DG et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med 2005; 202: 1279-1288. (Pubitemid 41586958)
5. Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol 2010; 11: 197-206.
6. Fuji N, Ueda Y, Fujiwara H, Itoh T, Yoshimura T, Yamagishi H. Antitumor effect of alpha-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver. Clin Cancer Res 2000; 6: 3380-3387. (Pubitemid 30637770)
7. Giaccone G, Punt CJA, Ando Y, Ruijter R, Nishi N, Peters M et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002; 8: 3702-3709. (Pubitemid 35424759)
8. Nakagawa R, Serizawa I, Motoki K, Sato M, Ueno H, Iijima R et al. Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells. Oncol Res 2000; 12: 51-58.
9. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M. Cutting edge: Inhibition of experimental tumor metastasis by dendritic cells pulsed with alphagalactosylceramide. J Immunol 1999; 163: 2387-2391. (Pubitemid 29399156)
10. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 2012; 12: 239-252.
11. Burdin N, Brossay L, Kronenberg M. Immunization with alpha- galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur J Immunol 1999; 29: 2014-2025. (Pubitemid 29265558)
12. Parekh VV, Wilson MT, Olivares-Villagomez D, Singh AK, Wu L, Wang CR et al. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 2005; 115: 2572-2583. (Pubitemid 41266220)
13. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosylceramide loaded mature dendritic cells in cancer patients. J Exp Med 2005; 201: 1503-1517. (Pubitemid 40664093)
14. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 2002; 3: 867-874.
15. Shimizu K, Goto A, Fukui M, Taniguchi M, Fujii S. Tumor cells loaded with alphagalactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. J Immunol 2007; 178: 2853-2861. (Pubitemid 46333163)
16. Mattarollo SR, West AC, Steegh K, Duret H, Paget C, Martin B et al. NKT cell adjuvantbased tumor vaccine for treatment of myc oncogene-driven mouse B cell lymphoma. Blood 2012; 120: 3019-3029.
17. Chung Y, Qin H, Kang CY, Kim S, Kwak LW, Dong C. An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. Blood 2007; 110: 2013-2019. (Pubitemid 47443916)
18. Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H et al. Intratumor depletion of CD4 + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005; 201: 779-791. (Pubitemid 40395122)
19. Azuma T, Takahashi T, Kunisato A, Kitamura T, Hirai H. Human CD4 + CD25+ regulatory T cells suppress NKT cell functions. Cancer Res 2003; 63: 4516-4520. (Pubitemid 36951023)
20. Khazaie K, von Boehmer H. The impact of CD4 +CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer. Sem Cancer Biol 2006; 16: 124-136. (Pubitemid 43172061)
21. Ly D, Mi QS, Hussain S, Delovitch TL. Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4 +CD25+ regulatory T cells. J Immunol 2006; 177: 3695-3704. (Pubitemid 44359901)
22. Ralainirina N, Poli A, Michel T, Poos L, Andres E, Hentges F et al. Control of NK cell functions by CD4 + CD25+ regulatory T cells. J Leukoc Biol 2007; 81: 144-153. (Pubitemid 46021263)
23. Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI, Hayakawa Y. CD4 + CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 2006; 176: 1582-1587. (Pubitemid 43134302)
24. Petersen TR, Sika-Paotonu D, Knight DA, Dickgreber N, Farrand KJ, Ronchese F et al. Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand. Immunol Cell Biol 2010; 88: 596-604.
25. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999; 59: 3128-3133. (Pubitemid 29316012)
26. Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med 2008; 205: 2125-2138.
27. Lahl K, Loddenkemper C, Drouin C, Freyer J, Arnason J, Eberl G et al. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J ExpMed 2007; 204: 57-63. (Pubitemid 46148756)
28. Moreno M, Molling JW, von Mensdorff-Pouilly S, Verheijen RH, Hooijberg E, Kramer D et al. IFN-gamma-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses. J Immunol 2008; 181: 2446-2454.
29. O'Connor Jr. W, Kamanaka M, Booth CJ, Town T, Nakae S, Iwakura Y et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 2009; 10: 603-609.
30. Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, Ngiow SF et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res 2010; 70: 7788-7799.
31. Nagai H, Horikawa T, Hara I, Fukunaga A, Oniki S, Oka M et al. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp Dermatol 2004; 13: 613-620. (Pubitemid 39345270)
32. Lahl K, Sparwasser T. In vivo depletion of FoxP3+ Tregs using the DEREG mouse model. Methods Mol Biol 2011; 707: 157-172.
33. Overwijk WW, de Visser KE, Tirion FH, de Jong LA, Pols TW, van der Velden YU et al. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol 2006; 176: 5213-5222.
34. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003; 198: 569-580. (Pubitemid 37040391)
35. Hayakawa Y, Godfrey DI, Smyth MJ. Alpha-galactosylceramide: Potential immunomodulatory activity and future application. Curr Med Chem 2004; 11: 241-252. (Pubitemid 38128847)
36. Hayakawa Y, Rovero S, Forni G, Smyth MJ. Alpha-galactosylceramide (KRN7000) suppression of chemical-and oncogene-dependent carcinogenesis. Proc Nat Acad Sci USA 2003; 100: 9464-9469. (Pubitemid 37033951)
37. Shimizu K, Kurosawa Y, Taniguchi M, Steinman RM, Fujii S. Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J Exp Med 2007; 204: 2641-2653. (Pubitemid 350063944)
38. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis. Br J Cancer 2011; 105: 93-103.
39. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-1570.
40. Yu P, Fu YX. Tumor-infiltrating T lymphocytes: Friends or foes? Lab Invest 2006; 86: 231-245. (Pubitemid 43276955)
41. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-113.
42. Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 2011; 71: 4809-4820.
43. Kim J, Lahl K, Hori S, Loddenkemper C, Chaudhry A, deRoos P et al. Cutting edge: Depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice. J Immunol 2009; 183: 7631-7634.
44. Awasthi A, Kuchroo VK. IL-17A directly inhibits TH1 cells and thereby suppresses development of intestinal inflammation. Nat Immunol 2009; 10: 568-570.
45. Moody DB, Briken V, Cheng TY, Roura-Mir C, Guy MR, Geho DH et al. Lipid length controls antigen entry into endosomal and nonendosomal pathways for CD1b presentation. Nat Immunol 2002; 3: 435-442. (Pubitemid 34520792)
46. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115: 3623-3633. (Pubitemid 43121851)
47. Mahnke K, Schonfeld K, Fondel S, Ring S, Karakhanova S, Wiedemeyer K et al. Depletion of CD4 +CD25+ human regulatory T cells in vivo: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 2007; 120: 2723-2733. (Pubitemid 46651297)
48. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, Lyerly HK et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008; 112: 610-618.
49. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2005; 11: 1910-1917. (Pubitemid 40471857)
50. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K et al. Therapeutic activation of V{alpha}24+V{beta}11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004; 103: 383-389. (Pubitemid 38140063)
51. Stewart TJ, Abrams SI. Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. J Immunol 2007; 179: 2851-2859.
52. Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001; 13: 459-463. (Pubitemid 32288543)